A detailed history of Black Rock Inc. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,023,626 shares of NUVL stock, worth $276 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,023,626
Previous 2,708,458 11.64%
Holding current value
$276 Million
Previous $203 Million 12.78%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$62.76 - $81.61 $19.8 Million - $25.7 Million
315,168 Added 11.64%
3,023,626 $229 Million
Q1 2024

May 10, 2024

SELL
$72.35 - $88.99 $921,521 - $1.13 Million
-12,737 Reduced 0.47%
2,708,458 $203 Million
Q4 2023

Feb 13, 2024

BUY
$42.42 - $80.28 $12.4 Million - $23.4 Million
291,216 Added 11.98%
2,721,195 $200 Million
Q3 2023

Nov 13, 2023

BUY
$39.12 - $49.85 $1.3 Million - $1.65 Million
33,115 Added 1.38%
2,429,979 $112 Million
Q2 2023

Aug 11, 2023

BUY
$23.58 - $44.68 $4.74 Million - $8.98 Million
200,966 Added 9.15%
2,396,864 $101 Million
Q1 2023

May 12, 2023

BUY
$25.42 - $33.52 $487,021 - $642,209
19,159 Added 0.88%
2,195,898 $57.3 Million
Q4 2022

Feb 13, 2023

BUY
$18.46 - $36.37 $14.1 Million - $27.8 Million
765,185 Added 54.21%
2,176,739 $64.8 Million
Q3 2022

Nov 14, 2022

BUY
$13.55 - $19.92 $1.4 Million - $2.06 Million
103,548 Added 7.92%
1,411,554 $27.4 Million
Q2 2022

Aug 12, 2022

BUY
$7.4 - $15.07 $374,018 - $761,683
50,543 Added 4.02%
1,308,006 $17.7 Million
Q1 2022

May 12, 2022

BUY
$11.65 - $19.57 $3.4 Million - $5.71 Million
291,821 Added 30.22%
1,257,463 $17.5 Million
Q4 2021

Feb 10, 2022

BUY
$18.01 - $30.1 $5.63 Million - $9.41 Million
312,512 Added 47.85%
965,642 $18.4 Million
Q3 2021

Nov 09, 2021

BUY
$18.25 - $38.35 $11.9 Million - $25 Million
653,130 New
653,130 $14.7 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.92B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.